medigraphic.com
ISSN 1684-1824 (Electronic)

2019, Number 4

<< Back Next >>

Rev Méd Electrón 2019; 41 (4)

New challenges in the treatment of the infection for Helicobacter pylori

Avalos GR, Vanterpool HM, Morales DM, Lamoth WI, Prendes HA

Language: Portugu?s
References: 31
Page: 979-992
PDF size: 748.60 Kb.


ABSTRACT

The infection for Helicobacter pylori affects approximately to the world population's 50%, it is causing of chronic gastritis, peptic ulcer, gastric cancer and linfoma associated to the mucous one. From their discovery, the eradication has been one of the most important challenges in Gastroenterología. In many countries the prevalencia of primary resistance is ignored from the microorganism to the different antibiotics that empirically they are used, and for not carrying out routine tests that verify its eradication in the daily practice, the effectiveness of the prescribed outlines it is ignored. The progressive increment of the resistance to the claritromicina and metronidazol, together to an absence of alternative antibioticotherapy, challenges the capacity to eliminate from an effective way to this bacteria. The bismuth subcitrato has resurged and its addition in the therapy has allowed to increase the cure rates above 90%. At the moment it is invoked that to improve the effectiveness in the treatment, that is should combine a potent suppression of the gastric acid in combined quadruple treatments with a duration of 14 days, for most of the cases. The adherence to the treatment is crucial to obtain therapeutic good results.


REFERENCES

  1. Piñol Jiménez F, Salvador Prato JC, Paniagua Estévez M. Características de la infección por helicobacter pylori en pacientes con adenocarcinoma gástrico. Rev Cubana Med [Internet]. 2005 [citado 10/08/2016];44(5-6). Disponible: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S00347523200500050002

  2. Driggs Sánchez D, Cruz Aguilar T, Laurencio González I. Infección por Helicobacter pylori y cáncer gástrico. CCM [Internet]. 2013 [citado 10/08/2016];17(2):189-91. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S156043812013000200010&lng =es

  3. Navarro-Jarabo JM, Fernández-Sánchez F, Fernández-Moreno N, et al. Prevalence of primary resistance of Helicobacter pylori to clarithromycin and levofloxacin in Southern Spain. Digestion. 2015;92(2):78-82. Citado en: PubMed; PMID:26227669.

  4. Mitchell H, Katelaris P. Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. Med J Aust. 2016;204(10):376-380. Citado en: PubMed; PMID: 27256648.

  5. Prescrire Int. Helicobacter pylori and gastric or duodenal ulcer. Prescrire Int. 2016;25(167):18-23. Citado en: PubMed; PMID: 26942258.

  6. Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol [Internet]. 2017 [citado 12/06/2017]; 112(2):212–38. Disponible en: https://journals.lww.com/ajg/Fulltext/2017/02000/ACG_Clinical_Guideline__Treatment _of_Helicobacter.12.aspx

  7. Gisbert JP, Molina-Infante J, Amador J, et al. IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterol Hepatol [Internet]. 2017 [citado 12/06/2017];40:37810. Disponible en: https://www.elsevier.es/es-revista-gastroenterologia-hepatologia-14-avance-resumeniv- conferencia-espanola-consenso-sobre-S0210570516300589

  8. Malfertheiner P, Megraud F, O Morain CA, et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut [Internet]. 2016 [citado 12/06/2017];0:1–25. Disponible en: https://api.hiv.plus/uploads/79ba9e14b51546ec8aa998a237fe7eb8.pdf

  9. Fallone CA, Chiba N, Veldhuyzen van Zanten S, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69. Citado en: PubMed; PMID: 27102658.

  10. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence og helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514-33. Citado en: PubMed; PMID:26694080.

  11. Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212–38. Citado en: PubMed PMID; 28071659.

  12. Coticchia JM, Sugawa C, Tran VR, et al. Presence and density of Helicobacter pylori biofilms in human gastric mucosa in patients with peptic ulcer. J Gastrointest Surg. 2006;10 6):883-89. Citado en: PubMed; PMID: 16769546.

  13. Navarro-Jarabo JM, Fernández-Sánchez F, Fernández-Moreno N, et al. Prevalence of primary resistance of Helicobacter pylori to clarithromycin and levofloxacin in Southern Spain. Digestion. 2015;92(2):78-82. Citado en: PubMed PMID: 26227669.

  14. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidencebased medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12(2):177-86. Citado en: PubMed PMID: 23751282.

  15. Molina-Infante J, Shiotani A. Practical Aspects in Choosing a Helicobacter pylori Therapy. Gastroenterol Clin North Am. 2015;44(3):519-535. Citado en: PubMed; PMID: 26314666.

  16. Crowe SE. Treatment regimens for Helicobacter pylori. UpToDate [Internet]; 2017 [citado 30/05/2017]. Disponible en: https://www.uptodate.com/contents/treatmentregimens- for-helicobacter-pylori

  17. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004;95(1):2-8. Citado en: PubMed; PMID: 15245569.

  18. Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43(10):1048-59. Citado en: PubMed PMID: 26991399.

  19. Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22(4):1-13. Citado en: PubMed PMID : 28464347.

  20. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;11(12). Citado en: PubMed PMID: 24338763.

  21. Molina-Infante J, Shiotani A. Practical aspects in choosing Helicobacter pylori therapy. Gastroenterol Clin NorthAm. 2015;44(3):519-35. Citado en: PubMed PMID: 26314666.

  22. Megraud F. The challenge of Helicobacter pylori resistance to antibiotics: The comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol. 2012;5(2):103-9. Citado en: PubMed PMID: 22423259.

  23. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazol, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomized, opelabel, non-inferiority, phase 3 trial. Lancet. 2011;378(9805):1778. Citado en PubMed PMID: 21345487.

  24. Agencia española de medicamentos y productos sanitarios. Ficha técnica: Pylera [Internet]. España: MINISTERIO DE SANIDAD, POLÍTICA SOCIAL E IGUALDAD; 2017 [citado 12/08/2017]. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/75095/FichaTecnica_75095.html.pdf

  25. Colectivo de autores. Nuevas pautas erradicadoras de helicobacter pylori. INFAC [Internet]. 201 7[citado 12/06/2017];25(5). Disponible en: http://www.euskadi.eus/contenidos/informacion/cevime_infac_2017/es_def/adjuntos/I NFAC_Vol%20_25%20_n_5_%20H%20pylori_es.pd.f.

  26. Ciccaglione AF, Tavani R, Grossi l, et al. Rifabutin containing Triple therapy and Rifabutin with Bismuth containing Quadruple therapy for third line treatment of helicobacter pylori infection: Two pilot studies. Helicobacter. 2016;21(5):375-81. Citado en: PubMed; PMID: 26807668.

  27. Fallone CA, Chiba N, Veldhuyzen Van Zanten S, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69. Citado en: PubMed; PMID: 27102658.

  28. Koletzko S, Jones NL, Goodman K, et al. On behalf of the H. pylori working groups of ESPGHAN and NASPGHAN. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. JPediatr Gastroenterol Nutr. 2011;53(2):230-43. Citado en: PubMed; PMID: 21558964.

  29. Ros Arnal I. Patología relacionada con el gluten. Actualización en Helicobacter pylori. En: Pap AE (ed.). Curso Actualización Pediátrica. Madrid: Lúa Ediciones; 2017.

  30. Takeuchi T, Umegaki E, Takeuchi N, et al. Strategies for peptic ulcer healing after 1 week proton pump inhibitor-based triple Helicobacter pylori eradication therapy in Japanese patients: Differences of gastric ulcers and duodenal ulcers. J Clin Biochem Nutr. 2012;51(3):189-95. Citado en: PubMed; PMID: 23170046.

  31. Gisbert JP, Khorrami S, Carballo F, et al. Meta-analysis: helicobacterpylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther. 2004;19(6):617-29. Citado en: PubMed; PMID: 15023164.




2020     |     www.medigraphic.com